Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease
Identifieur interne : 003947 ( Main/Exploration ); précédent : 003946; suivant : 003948Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease
Auteurs : William G. Ondo [États-Unis] ; Ron Tintner [États-Unis] ; Kevin Dat Voung [États-Unis] ; Dejian Lai [États-Unis] ; George Ringholz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antipsychotic Agents (adverse effects), Brief Psychiatric Rating Scale, Dibenzothiazepines (adverse effects), Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Evaluation, Female, Hallucination, Hallucinations (chemically induced), Humans, Male, Middle Aged, Nervous system diseases, Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Placebo, Placebos, Psychosis, Questionnaires, Quetiapine, Treatment Outcome, hallucinations, psychosis, quetiapine.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Dibenzothiazepines.
- chemically induced : Hallucinations.
- drug therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Evaluation, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Placebos, Questionnaires, Treatment Outcome.
Abstract
We completed a single site, double‐blind, placebo‐controlled, parallel design study of quetiapine for hallucinations in PD. Thirty‐one subjects with PD and prominent visual hallucinations and Mini‐Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug‐related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20474
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001585
- to stream Istex, to step Curation: 001585
- to stream Istex, to step Checkpoint: 002357
- to stream PubMed, to step Corpus: 003094
- to stream PubMed, to step Curation: 003094
- to stream PubMed, to step Checkpoint: 003159
- to stream Ncbi, to step Merge: 001207
- to stream Ncbi, to step Curation: 001207
- to stream Ncbi, to step Checkpoint: 001207
- to stream Main, to step Merge: 005034
- to stream PascalFrancis, to step Corpus: 001E16
- to stream PascalFrancis, to step Curation: 000F05
- to stream PascalFrancis, to step Checkpoint: 001E73
- to stream Main, to step Merge: 005351
- to stream Main, to step Curation: 003947
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name></author><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name></author><author><name sortKey="Dat Voung, Kevin" sort="Dat Voung, Kevin" uniqKey="Dat Voung K" first="Kevin" last="Dat Voung">Kevin Dat Voung</name></author><author><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name></author><author><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:685E14C6054AD3E026D06495E1904DB0DD581355</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20474</idno><idno type="url">https://api.istex.fr/document/685E14C6054AD3E026D06495E1904DB0DD581355/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001585</idno><idno type="wicri:Area/Istex/Curation">001585</idno><idno type="wicri:Area/Istex/Checkpoint">002357</idno><idno type="wicri:doubleKey">0885-3185:2005:Ondo W:double:blind:placebo</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15800937</idno><idno type="wicri:Area/PubMed/Corpus">003094</idno><idno type="wicri:Area/PubMed/Curation">003094</idno><idno type="wicri:Area/PubMed/Checkpoint">003159</idno><idno type="wicri:Area/Ncbi/Merge">001207</idno><idno type="wicri:Area/Ncbi/Curation">001207</idno><idno type="wicri:Area/Ncbi/Checkpoint">001207</idno><idno type="wicri:doubleKey">0885-3185:2005:Ondo W:double:blind:placebo</idno><idno type="wicri:Area/Main/Merge">005034</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0443835</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E16</idno><idno type="wicri:Area/PascalFrancis/Curation">000F05</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E73</idno><idno type="wicri:doubleKey">0885-3185:2005:Ondo W:double:blind:placebo</idno><idno type="wicri:Area/Main/Merge">005351</idno><idno type="wicri:Area/Main/Curation">003947</idno><idno type="wicri:Area/Main/Exploration">003947</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Dat Voung, Kevin" sort="Dat Voung, Kevin" uniqKey="Dat Voung K" first="Kevin" last="Dat Voung">Kevin Dat Voung</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Emory University School of Medicine, Department of Neurology, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="958">958</biblScope><biblScope unit="page" to="963">963</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">685E14C6054AD3E026D06495E1904DB0DD581355</idno><idno type="DOI">10.1002/mds.20474</idno><idno type="ArticleID">MDS20474</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (adverse effects)</term><term>Brief Psychiatric Rating Scale</term><term>Dibenzothiazepines (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Evaluation</term><term>Female</term><term>Hallucination</term><term>Hallucinations (chemically induced)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Placebo</term><term>Placebos</term><term>Psychosis</term><term>Questionnaires</term><term>Quetiapine</term><term>Treatment Outcome</term><term>hallucinations</term><term>psychosis</term><term>quetiapine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Brief Psychiatric Rating Scale</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Placebos</term><term>Questionnaires</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Hallucination</term><term>Parkinson maladie</term><term>Placebo</term><term>Psychose</term><term>Quétiapine</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We completed a single site, double‐blind, placebo‐controlled, parallel design study of quetiapine for hallucinations in PD. Thirty‐one subjects with PD and prominent visual hallucinations and Mini‐Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug‐related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name></region><name sortKey="Dat Voung, Kevin" sort="Dat Voung, Kevin" uniqKey="Dat Voung K" first="Kevin" last="Dat Voung">Kevin Dat Voung</name><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:685E14C6054AD3E026D06495E1904DB0DD581355
|texte= Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |